Advanced Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene

DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

July 2024:- Hoffmann-La Roche- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma. The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
July 2024:- AbbVie- A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment.
DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
The leading Advanced Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
Promising Advanced Hepatocellular Carcinoma Therapies such as Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs

Advanced Hepatocellular Carcinoma Emerging Drugs

Tivozanib : AVEO Oncology

FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Nofazinlimab: CStone Pharmaceuticals

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.

ECT 204: Eureka Therapeutics

ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Sintilimab: Eli Lilly and Company/Innovent

Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.

Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking Advanced Hepatocellular Carcinoma Research and development projects @ Advanced Hepatocellular Carcinoma Unmet Needs

Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Discover the latest advancements in Advanced Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

Coverage- Global
Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
Advanced Hepatocellular Carcinoma Therapies- Tremelimumab, Durvalumab, Bevacizumab, Livmoniplimab, GT90001, Ori-C101, IBI310, Sintilimab, Sorafenib, and others.
Advanced Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Hepatocellular Carcinoma Pipeline on our website @ Advanced Hepatocellular Carcinoma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Advanced Hepatocellular Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Pre-Registration)
Drug name: Company Name
Drug profiles in the detailed report…..
Last Stage Products (Phase III)
Nofazinlimab: CStone Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
Tivozanib : AVEO Oncology
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Advanced Hepatocellular Carcinoma Key Companies
Advanced Hepatocellular Carcinoma Key Products
Advanced Hepatocellular Carcinoma – Unmet Needs
Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
Advanced Hepatocellular Carcinoma Analyst Views
Advanced Hepatocellular Carcinoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×